From Our 2008 Archives
Child Anxiety: Therapy Plus Zoloft Best
Latest Healthy Kids News
Study Shows Cognitive Behavioral Therapy, Zoloft Work for Child Anxiety -- But Combo Is Best
Daniel J. DeNoon
Reviewed By Louise Chang, MD
Dec. 24, 2008 - Cognitive behavioral therapy (CBT) and Zoloft are effective treatments for childhood anxiety disorders -- but the combination works best, a government-funded study shows.
That's why Johns Hopkins researcher John T. Walkup, MD, and colleagues led a multi-institution, government-funded study to see whether combination treatment would help.
There were four different treatment groups:
After 12 weeks:
Walkup and colleagues conclude that all three of the active treatments -- CBT, Zoloft, or the combination -- are effective short-term treatments for kids with anxiety disorders.
"Among these effective therapies, combination therapy provides the best chance for a positive outcome," they conclude.
Zoloft treatment worked the fastest, with rapid initial improvement but little additional improvement after eight weeks of treatment. CBT took eight to 12 weeks to work.
Most kids with anxiety disorders don't get diagnosed or treated, notes an editorial by Graham J. Emslie, MD, of the University of Texas Southwestern Medical Center, Dallas.
That's too bad, he says, because research now shows that untreated childhood anxiety persists into adulthood.
"This trial answers the most compelling question about the treatment of anxiety disorders: Treatment is indicated," Emslie states.
Zoloft is an SSRI antidepressant. Like other members of its class, the drug has been linked to suicidal thoughts in children and adults. But in the Walkup study, there were no more suicidal thoughts in kids taking Zoloft than in kids taking placebo pills.
However, kids taking Zoloft reported more insomnia, fatigue, sedation, and restlessness than kids in the CBT group.
Zoloft is made by Pfizer. Pfizer provided the Zoloft and placebo pills used in the study, but did not provide other support for the study and was not involved in the design or implementation of the study. Walkup and colleagues report receiving various fees and research support from various pharmaceutical companies.
The study findings, and the Emslie editorial, appear in the Dec. 25 issue of the New England Journal of Medicine.
SOURCES: Walkup, J.T. New England Journal of Medicine, Dec. 25, 2008; vol 359: pp 2853-66. Emslie, G.J. New England Journal of Medicine, Dec. 25, 2008; vol 359: pp 2835-2836.
©2008 WebMD, LLC. All Rights Reserved.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions